Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 12 (1) , 58-63
Abstract
To establish whether the combination of a corticosteroid (dexamethasone) and the newer serotonin-3 (5-HT3) receptor antagonist ramosetron is superior to ramosetron alone in controlling cisplatin-induced emesis. A total of 283 patients aged 18–75 years with confirmed malignant disease who were scheduled to receive cisplatin ≥50 mg/m2 with or without other antineoplastic agents were randomized to intravenous treatment with either ramosetron 300 μg plus dexamethasone 20 mg (n=149) or ramosetron 300 μg alone (n=134) given 30 min prior to cisplatin infusion. If vomiting occurred in the following 24 h, patients in both groups received an intravenous rescue dose of ramosetron 300 μg. Subsequently, on days 2 and 3, treatment was continued orally with either ramosetron 100 μg once daily plus dexamethasone 8 mg twice daily, or ramosetron 100 μg once daily. During the first 24 h after cisplatin infusion, significantly more patients receiving combination therapy had a complete response (no nausea or vomiting or requirement for rescue therapy) than those receiving ramosetron alone (68% vs 54%, respectively; P=0.034), and significantly fewer patients needed a rescue dose of ramosetron (22% vs 34%, respectively; P=0.032). In addition, the percentages of patients with no nausea and no vomiting were significantly greater in the ramosetron plus dexamethasone group than in the ramosetron-alone group at both 24 h and 72 h after cisplatin administration. The antiemetic efficacy of ramosetron in cancer patients receiving highly emetogenic cisplatin chemotherapy is significantly enhanced by its use in combination with dexamethasone.Keywords
This publication has 17 references indexed in Scilit:
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesisAnti-Cancer Drugs, 1998
- A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesisCancer Chemotherapy and Pharmacology, 1996
- Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.1995
- Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994
- A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.Journal of Clinical Oncology, 1994
- The use of ondansetron in patients receiving multiple-day cisplatin regimens.1992
- Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.Journal of Clinical Oncology, 1991
- Analysis of tissue platinum distribution in patients with cancer of the oesophagusEuropean Journal of Cancer and Clinical Oncology, 1991
- Side effects and emotional distress during cancer chemotherapyCancer, 1989